Skip to main content
. 2024 Jan 11;2:1280993. doi: 10.3389/frtra.2023.1280993

Figure 2.

Figure 2

OS by immunosuppression regimen in PTLD case-control cohort. (A) OS from date of transplant in PTLD cases (n = 7) and matched controls (renal transplant recipients, n = 14) from selected cohort of patients with detailed clinical and survival data. (B) OS from PTLD diagnosis in PTLD cases with detailed clinical and survival data (n = 10). Bela, belatacept; tac, tacrolimus-containing regimens.